We’re heading to Nashville to participate in this year’s ALK Positive Inc. Summit! This weekend, we’ll connect with experts, patients and caregivers as we explore the latest in ALK+ NSCLC research and cancer care. Register to join virtually: https://bit.ly/3W4oIkM #StrongerTogether #ALKSummit24 #LungCancer
Nuvalent, Inc.
Biotechnology Research
Cambridge, Massachusetts 4,382 followers
#PreciselyTargetedTherapies for patients with cancer
About us
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. To learn more, visit www.nuvalent.com.
- Website
-
https://www.nuvalent.com/
External link for Nuvalent, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
- Founded
- 2017
Locations
-
Primary
One Broadway 14th Floor
Cambridge, Massachusetts 02142, US
Employees at Nuvalent, Inc.
Updates
-
✈️ Join us in Barcelona at this year’s ESMO - European Society for Medical Oncology Congress for updated clinical and preclinical data for our ROS1-selective inhibitor, zidesamtinib, and a clinical data update for our ALK-selective inhibitor, NVL-655! Learn more: https://lnkd.in/eENE_MCd #ESMO24 #biotech #oncology #NSCLC
-
-
We are delighted to announce Henry Pelish’s promotion to Chief Scientific Officer, reflecting his significant contributions at Nuvalent! A member of the #NuCrew from the start, Henry’s vision and leadership have helped shape our approach and fuel our pipeline of novel, precisely targeted kinase inhibitors. Read more here: https://lnkd.in/d8dHHSjh #biotech #oncology $NUVL #leadership
-
-
The #NuCrew had a blast participating in Bio-Ball 2024 to support Special Olympics Massachusetts — and we’re already practicing for next year’s tournament! 🏀
-
-
#NuCrewOutings in New York! 😎 What a great opportunity to celebrate everything we’ve achieved as a team, cheers to the amazing journey ahead! $NUVL #biotech #oncology
-
-
📣 The #NuCrew is hiring! We are on the lookout for a Director, Clinical Operations Excellence and Compliance! 👀 Learn more about this role and other new opportunities here: https://lnkd.in/ehFYXCJe #NuTalent #hiring #biotech
-
-
HOT JOB ALERT 🚨Senior Accountant🚨 Interested in joining the #NuCrew? Learn more about this role and other new opportunities here: https://lnkd.in/egUVzzZT #NuTalent #hiring #biotech
-
-
The #NuCrew is ready! We have our game faces on and look forward to meeting everyone on the court! 🏀
No Chemistry S2 Episode 4 On our last episode of season two of No Chemistry, we introduce the final four remaining teams of 2024 Bio-Ball - Sanofi/Shrewsbury, 2seventy bio/Wareham, Nuvalent, Inc./Whitney Academy, and a mystery team/Hockomock Huskies. Mail Time: How do I make sure that my biotech company raises enough money to get to the Garden? Fundraise, fundraise, FUNDRAISE! The challenge ends when the last CEO attempts a free throw basket. See you Friday! Special Olympics Massachusetts Gregg Beloff Steve Huftalen #bioball Alcyone Therapeutics Inc. Alnylam Pharmaceuticals Apellis Pharmaceuticals Blueprint Medicines BlueRock Therapeutics Flagship Pioneering Kelonia Therapeutics Nimbus Therapeutics Sage Therapeutics Seres Therapeutics Tome Biosciences Third Rock Ventures Commonwealth Financial Group